AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-_targeting agents in human metastatic breast cancer models
- PMID: 23990115
- DOI: 10.1158/1535-7163.MCT-12-1178
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-_targeting agents in human metastatic breast cancer models
Abstract
Breast cancer is the most prevalent malignancy affecting women and ranks second in cancer-related deaths, in which death occurs primarily from metastatic disease. Triple-negative breast cancer (TNBC) is a more aggressive and metastatic subtype of breast cancer that is initially responsive to treatment of microtubule-_targeting agents (MTA) such as taxanes. Recently, we reported the characterization of AMG 900, an orally bioavailable, potent, and highly selective pan-Aurora kinase inhibitor that is active in multidrug-resistant cell lines. In this report, we investigate the activity of AMG 900 alone and in combination with two distinct classes of MTAs (taxanes and epothilones) in multidrug-resistant TNBC cell lines and xenografts. In TNBC cells, AMG 900 inhibited phosphorylation of histone H3 on Ser(10), a proximal substrate of Aurora-B, and induced polyploidy and apoptosis. Furthermore, AMG 900 potentiated the antiproliferative effects of paclitaxel and ixabepilone at low nanomolar concentrations. In mice, AMG 900 significantly inhibited the growth of MDA-MB-231 (F(11); parental), MDA-MB-231 (F(11)) PTX-r (paclitaxel-resistant variant), and DU4475 xenografts. The combination of AMG 900 with docetaxel enhanced tumor inhibition in MDA-MB-231 (F(11)) xenografts compared with either monotherapy. Notably, combining AMG 900 with ixabepilone resulted in regressions of MDA-MB-231 (F(11)) PTX-r xenografts, in which more than 50% of the tumors failed to regrow 75 days after the cessation of drug treatment. These findings suggest that AMG 900, alone and in combination with MTAs, may be an effective intervention strategy for the treatment of metastatic breast cancer and provide potential therapeutic options for patients with multidrug-resistant tumors.
©2013 AACR.
Similar articles
-
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Cancer Res. 2010 Dec 1;70(23):9846-54. doi: 10.1158/0008-5472.CAN-10-3001. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935223
-
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.J Transl Med. 2014 Nov 4;12:307. doi: 10.1186/s12967-014-0307-x. J Transl Med. 2014. PMID: 25367255 Free PMC article.
-
Dual _targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.Mol Cancer Ther. 2018 Dec;17(12):2575-2585. doi: 10.1158/1535-7163.MCT-18-0186. Epub 2018 Sep 28. Mol Cancer Ther. 2018. PMID: 30266802 Free PMC article.
-
Preclinical investigations with epothilones in breast cancer models.Semin Oncol. 2008 Apr;35(2 Suppl 2):S15-21; quiz S39. doi: 10.1053/j.seminoncol.2008.02.002. Semin Oncol. 2008. PMID: 18410795 Review.
-
Preclinical discovery of ixabepilone, a highly active antineoplastic agent.Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Cancer Chemother Pharmacol. 2008. PMID: 18347795 Review.
Cited by
-
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation.RSC Adv. 2024 Jul 8;14(30):21668-21681. doi: 10.1039/d4ra03459g. eCollection 2024 Jul 5. RSC Adv. 2024. PMID: 38979468 Free PMC article.
-
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers.Nat Cancer. 2024 Jan;5(1):66-84. doi: 10.1038/s43018-023-00699-5. Epub 2023 Dec 27. Nat Cancer. 2024. PMID: 38151625 Free PMC article.
-
Recent advances in hyaluronic acid-decorated nanocarriers for _targeted cancer therapy.Drug Discov Today. 2017 Apr;22(4):665-680. doi: 10.1016/j.drudis.2016.12.009. Epub 2016 Dec 23. Drug Discov Today. 2017. PMID: 28017836 Free PMC article. Review.
-
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7. Invest New Drugs. 2018. PMID: 29980894 Free PMC article. Clinical Trial.
-
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.Am J Hematol. 2017 Jul;92(7):660-667. doi: 10.1002/ajh.24736. Epub 2017 Jun 5. Am J Hematol. 2017. PMID: 28370201 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous